Olanzapine, weight change and metabolic effects: a naturalistic 12-month follow up

Abstract

Objective: Olanzapine is an atypical antipsychotic drug used to treat schizophrenia. Some of the adverse effects related to its use are obesity, hyperlipidemia, type 2 diabetes and hypertension, which may result in development of metabolic syndrome. This study aimed to investigate a possible increase in some anthropometric and biochemical parameters, and the existence of any correlation between them in Brazilian patients with schizophrenia treated with olanzapine in the mid term. Methods: Thirty subjects with schizophrenia were evaluated, 16 women and 14 men, aged between 18 and 47 years. All patients underwent blood collection and anthropometric measurements at four different times during 12 months of follow up; thus each patient was his or her own control. Results: Evaluation of some anthropometric measurements showed significant differences when comparing the mean values obtained in each of the different data collection times (p < 0.05). However, the biochemical indicators of development of metabolic syndrome measured in our study did not show the same rate of increment, with only the total cholesterol and glucose levels presenting statistically significant changes (p < 0.05), but without the same magnitude of weight change. Conclusion:We conclude that medium-term treatment with olanzapine promoted a substantial weight gain and increased visceral fat, while the metabolic profile did not show the same magnitude of change, suggesting a dissociation between weight gain and blood parameters, despite the severe weight gain observed among subjects evaluated.

Quality of Life and Hormonal, Biochemical, and Anthropometric Profile Between Olanzapine and Risperidone Users

“…Other studies have associated anthropometric and biochemical changes with the use of olanzapine [23,24]. The application of the Simpson-Angus and UKU scales in this study confirmed the presence of extrapyramidal effects in olanzapine compared with risperidone users.…”

Olanzapine-Induced Activation of Hypothalamic Astrocytes and Toll-Like Receptor-4 Signaling via Endoplasmic Reticulum Stress Were Related to Olanzapine-Induced Weight Gain

“…Antipsychotics, in particular olanzapine, are the most commonly used medications in the treatment of schizophrenia (Lieberman et al, 2005). However, olanzapine treatment induces significant weight gain/obesity side effects (Albaugh et al, 2006;Salviato Balbao et al, 2014;Li et al, 2018). Previous studies have reported that olanzapine-induced obesity involves a complex network of neuron signals including the histamine H1 receptor (He et al, 2014), H3 receptors (Poyurovsky et al, 2005(Poyurovsky et al, , 2013Lian et al, 2014), the serotonin 5-HT2C receptor (Lord et al, 2017), ghrelin-mediated growth hormone secretagog receptor (GHS-R) (Zhang et al, 2014b;Tagami et al, 2016), and the cannabinoid 1 receptor (Lazzari et al, 2017).…”

Metabolic Side Effects of Olanzapine in Patients With Psychotic Disorders in Oman: A Retrospective Cohort Study

“…Non-significant lipid changes (triglycerides, HDL-C, LDL-C) with olanzapine in Brazilian patients with schizophrenia were also observed. 36 These results, however, contradict what has been reported by others 37 who observed dose-dependent weight gains and lipid changes associated with olanzapine and clozapine in patients with psychotic disorders. The impact of other measured (age, gender, diabetes mellitus, other AAPs) and unmeasured (lifestyle and environmental factors) confounding variables could have affected the results.…”